Williams syndrome is a neurodevelopmental disorder due to the deletion of a ~1.5 Mb region of chromosome band 7q11.23. Although the features of WS are ultimately due to the decreased copy number of the ~25 genes, the critical downstream biological pathways that alter development and adult function are unknown. WS provides a unique human model in which to combine high resolution array analyses to determine the components of these pathways. In this study, we determined the deletion in a cohort of 19 subjects with WS and asked whether genome-wide approaches querying 22,000 genes at the single exon level, were capable of sensitively measuring alterations of two fold reduction in single gene transcripts. Whole genome gene expression analysis was performed on total RNA samples from 19 WS DNAs with the common deletion and 8 normal controls. RNAs were labeled using a whole transcript sense target labeling assay after an rRNA reduction. Biotinylated target was hybridized to the Affymetrix GeneChip Exon 1.0 ST (sense target) arrays containing 6.5 million probe features. Probe level data was processed with RMA analysis (Robust Multiarray Analysis) for 22,000 RefSeq supported genes, and for exon-level results. Unexpectedly, rank products analysis (RP) revealed a 25-50% (1-2 fold) reduction in expression levels across chromosome 7 Williams region transcripts as the most significant genomewide reduction observed between normal and affected groups. Of 22,000 gene transcripts queried, WS genes represented 10 of the top 11 transcripts with reduced expression. These data indicate that genome wide analyses can be used to establish both deleted genes and non-deleted genes whose transcription is altered, providing the opportunity to identify genetic networks that mediate the features of WS.
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Goals
1. To determine genome-wide gene expression in a cohort of 19 subjects with WS and 8 normal controls. 2. To determine if arrays of 22,000 genes were capable of measuring 50% decrease in WS transcripts.
Materials and Methods
Patient population and total RNA preparation
Our population includes 19 WS patients and 8 controls (a subset of the parents who transmitted the normal chromosome 7). The subjects and their families were recruited as part of an ongoing research study approved by the Institutional Review Boards at Cedars-Sinai Medical Center or The Salk Institute. In each case the diagnosis of WS was determined by medical history, clinical and laboratory evidence and was then confirmed by multicolor FISH. Immortalized lymphoblast cell lines from each of 19 WS and 8 normal controls were generated and cultivated under standardized conditions. The cells were grown in RMPI 1640 with 10% FBS, 5% pen/strep, 5% L-glutamine, and 0.5% gentamycin. The total RNA was isolated by using the QIAGEN RNeasy Kit. RNAs were labeled using a whole transcript sense target labeling assay after an rRNA reduction. Biotinylated target was hybridized to the Affymetrix GeneChip Exon 1.0 ST (sense target) arrays containing 6.5 million probe features.
Affymetrix GeneChip
Probe level data were processed with RMA analysis (Robust Multiarray Analysis) for 22,000 RefSeq supported genes, and for exon-level results. As a first step, the probe-level data were analyzed by using robust multichip analyses. Then, the background was corrected and quantile was normalized across chips and subjects. Then the Summary step used normalized probe level measurements from step 1 to calculate metaprobeset transcript levels for a single gene. After robust filtering and annotating, the raw data were translated into the expression of each gene as shown in step 4.
TaqMan Gene Expression Assays, designed for human gene transcripts (Applied Biosystems, Foster City, CA), were used for quantifying gene expression of 12 WS genes. The assay mixture consisted of a TaqMan® MGB probe (labeled with FAMTM dye) and unlabeled polymerase chain reaction (PCR) primers for a specific human gene. BAZ1B  TBL2  MLXIPL  STX1A  CLDN3  CLDN4  RFC2  CLIP2  GTF2IRD1  WBSCR23  GTF2I  NCF1  WBSCR16 RT-PCR 
